VOYTICKY DAVID J 4
4 · Genesis Biopharma, Inc · Filed May 30, 2013
Insider Transaction Report
Form 4
VOYTICKY DAVID J
Director
Transactions
- Other
Common Stock
2013-05-22$0.01/sh+5,627,867$56,279→ 5,627,867 total - Other
12% Convertible Note due 2012
2013-05-22$0.01/sh−50,000$500
Footnotes (3)
- [F1]Outstanding debt of the reporting person, including interest and penalties thereon in an aggregate amount of $56,627.67, was converted into shares of Common Stock of the issuer pursuant to the terms of the Restructuring and Exchange Agreement, as further described on Current Report on Form 8-K filed with the SEC on May 29, 2013.
- [F2]Per share. Consideration for such shares paid by conversion of outstanding debt, including interest and penalties thereon, in an aggregate amount of $56,278.67.
- [F3]At the reporting person's sole discretion, the outstanding balance of the note may be converted into, or exchanged for, securities issued in the issuer's next capital raise on the same terms and conditions as are offered to any future investors, including to be determined, the rate of exchange.